Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

480 STUDY: Phase 2b Study of Locteron Plus Ribavirin to Treat Hepatitis C Virus (HCV) (480S)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Biolex Therapeutics, Inc.
ClinicalTrials.gov Identifier:
NCT00953589
First received: August 5, 2009
Last updated: February 1, 2012
Last verified: February 2012
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: January 2011
  Primary Completion Date: May 2010 (Final data collection date for primary outcome measure)